Taylor Sandison
Chief Tech/Sci/R&D Officer bei CIDARA THERAPEUTICS, INC.
Vermögen: 437 777 $ am 31.03.2024
Profil
Taylor Sandison is a professional with a doctorate degree from the University of Washington.
He started his career in 2010 as Director-Medical Affairs at Novartis Vaccines & Diagnostics, Inc. He then worked as Director-Clinical Science at Trius Therapeutics, Inc. from 2013 to 2014.
In 2014, he became Senior Medical Director at Cubist Pharmaceuticals LLC, where he worked until 2015.
The same year, he worked as Senior Medical Director at Merck & Co., Inc. for a brief period.
Since 2015, he has been working as Chief Medical Officer at Cidara Therapeutics, Inc.
Bekannte Unternehmensbeteiligungen
| Unternehmen | Datum | Anzahl der Aktien | Bewertung | Datum der Bewertung |
|---|---|---|---|---|
| 15.03.2024 | 475 845 ( 0,53% ) | 437 777 $ | 31.03.2024 |
Aktive Positionen von Taylor Sandison
| Unternehmen | Position | Beginn |
|---|---|---|
| CIDARA THERAPEUTICS, INC. | Chief Tech/Sci/R&D Officer | 01.01.2017 |
Ehemalige bekannte Positionen von Taylor Sandison
| Unternehmen | Position | Ende |
|---|---|---|
| MERCK & CO., INC. | Chief Tech/Sci/R&D Officer | 01.10.2015 |
| CUBIST PHARMACEUTICALS INC | Chief Tech/Sci/R&D Officer | 01.02.2015 |
Trius Therapeutics, Inc.
 Trius Therapeutics, Inc. Pharmaceuticals: MajorHealth Technology Trius Therapeutics, Inc. is a biopharmaceutical company which focuses on the discovery, development and commercialization of innovative antibiotics for life-threatening infections. It engages in developing tedizolid phosphate an intravenous, or IV, and oral antibiotic, for the treatment of serious gram-positive bacterial infections, initially for acute bacterial skin and skin structure infections, ABSSSI, and subsequently for other indications, including pneumonia. ABSSSI is a new classification for complicated skin and skin structure infections, or cSSSI. Tedizolid phosphate is an IV and orally administered second generation oxazolidinone. The company develops antibiotics for gram-negative infections. Trius Therapeutics was founded by John Finn and John P. Schmid in June 2004, and is headquartered in San Diego, CA. | Chief Tech/Sci/R&D Officer | 01.06.2014 |
Novartis Vaccines & Diagnostics, Inc.
 Novartis Vaccines & Diagnostics, Inc. Pharmaceuticals: MajorHealth Technology Novartis Vaccines & Diagnostics, Inc. manufactures and markets health care and nutritional products. The company was founded in 1986 and is headquartered in East Hanover, NJ. | Chief Tech/Sci/R&D Officer | 01.03.2013 |
Ausbildung von Taylor Sandison
| Dartmouth College | Undergraduate Degree |
| University of Washington | Doctorate Degree |
Erfahrungen
Besetzte Positionen
Aktive
Inaktive
Börsennotierte Unternehmen
Private Unternehmen
Beziehungen
Beziehungen ersten Grades
Unternehmen ersten Grades
Herr
Frau
Aufsichtsräte
Führungskräfte
Unternehmensverbindungen
| Börsennotierte Unternehmen | 2 |
|---|---|
| MERCK & CO., INC. | Health Technology |
| CIDARA THERAPEUTICS, INC. | Health Technology |
| Private Unternehmen | 3 |
|---|---|
Cubist Pharmaceuticals LLC
 Cubist Pharmaceuticals LLC Pharmaceuticals: MajorHealth Technology Cubist Pharmaceuticals LLC operates as a biopharmaceutical company. It focuses on the research, development and commercialization of pharmaceutical products. The company was founded in 1992 and is headquartered in Lexington, MA. | Health Technology |
Novartis Vaccines & Diagnostics, Inc.
Novartis Vaccines & Diagnostics, Inc. Pharmaceuticals: MajorHealth Technology Novartis Vaccines & Diagnostics, Inc. manufactures and markets health care and nutritional products. The company was founded in 1986 and is headquartered in East Hanover, NJ. | Health Technology |
Trius Therapeutics, Inc.
Trius Therapeutics, Inc. Pharmaceuticals: MajorHealth Technology Trius Therapeutics, Inc. is a biopharmaceutical company which focuses on the discovery, development and commercialization of innovative antibiotics for life-threatening infections. It engages in developing tedizolid phosphate an intravenous, or IV, and oral antibiotic, for the treatment of serious gram-positive bacterial infections, initially for acute bacterial skin and skin structure infections, ABSSSI, and subsequently for other indications, including pneumonia. ABSSSI is a new classification for complicated skin and skin structure infections, or cSSSI. Tedizolid phosphate is an IV and orally administered second generation oxazolidinone. The company develops antibiotics for gram-negative infections. Trius Therapeutics was founded by John Finn and John P. Schmid in June 2004, and is headquartered in San Diego, CA. | Health Technology |
